The U.S. Federal Trade Commission (FTC) has issued a proposed consent order requiring Indian drugmaker Aurobindo Pharma to divest four... Read more
Tag: #M&A
Bayer completes acquisition of Perfuse Therapeutics in a definitive $2.45 billion ophthalmology expansion
Global life science giant Bayer has officially finalized its corporate acquisition of biopharmaceutical enterprise Perfuse Therapeutics, Inc. Following the completion... Read more
Biogen targets immunology expansion with $1 billion buyout of RayThera
U.S.-listed biopharmaceutical enterprise Biogen Inc. has struck a definitive agreement to acquire privately-held biotechnology firm RayThera in a transaction valued... Read more
Healthcare PE firm Altaris to acquire AI drug development outfit Simulations Plus for $375 million
Specialized healthcare private equity firm Altaris has entered into a definitive agreement to acquire Simulations Plus, a global leader in... Read more
Eli Lilly accelerates M&A streak with acquisition of non-opioid pain drug developer 4E Therapeutics
U.S. pharmaceutical titan Eli Lilly and Company has announced a definitive agreement to acquire 4E Therapeutics, a biotechnology startup specializing... Read more
Gedeon Richter and Hetero Labs secure global alliance to develop and market generic Ozempic®
Gedeon Richter Plc. (Hungary) and Hetero Labs Ltd. (India) have officially announced the execution of a definitive global collaboration agreement... Read more
Chiesi Group finalizes $1.9 billion acquisition of KalVista Pharmaceuticals to expand rare disease footprint
Chiesi Group, an international research-focused biopharmaceutical corporation and certified B Corp, has officially finalized its corporate acquisition of KalVista Pharmaceuticals... Read more
AlzeCure enters potential $1 billion global out-licensing pact with Eli Lilly for Alzheimer’s drug
Swedish biotech AlzeCure Pharma has announced that it has entered into a definitive collaboration and global out-licensing agreement with Eli... Read more
GSK secures $10.6 billion takeover of Nuvalent to reinforce oncology pipeline with multi-blockbuster lung cancer assets
British drugmaker GSK has entered into a definitive agreement to acquire US-listed lung cancer biotechnology firm Nuvalent for an aggregate... Read more









